In­tra-Cel­lu­lar aims to raise $500M; Lil­ly’s Pre­vail cuts three part­nered pro­grams

Plus, news about TScan Ther­a­peu­tics, Con­nect Bio­Phar­ma, The­olyt­ics and Ul­ti­movacs:

In­tra-Cel­lu­lar Ther­a­pies seeks $500M of­fer­ing: Short­ly af­ter dis­clos­ing a Phase 3 win in de­pres­sion, which could lead to an ex­pand­ed la­bel for bipo­lar treat­ment Caply­ta, the biotech said it plans to raise one of the largest fol­low-on of­fer­ings of the year. The com­pa­ny’s stock $IT­CI closed 23% high­er on Tues­day. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER